Parathyroid hormone secretion during citrate anticoagulated hemodialysis in acutely ill maintenance hemodialysis patients

被引:17
作者
Apsner, R
Gruber, D
Hörl, WH
Sunder-Plassmann, G
机构
[1] Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria
[2] Univ Vienna, Dept Med Stat, Vienna, Austria
关键词
D O I
10.1213/01.ANE.0000132780.87036.F5
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Regional citrate anticoagulation during extracorporeal treatment is used inpatients at risk for hemorrhage. We conducted a prospective clinical trial on the effect of large-versus small-dose calcium supplementation during citrate anticoagulated hemodialysis on ionized calcium and intact parathyroid hormone (iPTH). Twenty-five treatments were studied in 25 patients with active bleeding or at risk for hemorrhage. Sixteen patients received large-dose calcium (15 mmol/h), and 9 received small-dose calcium (5 mmol/h) substitution during treatment. Ionized calcium increased in 13 of 16 patients in the large-dose calcium group and decreased in 8 of 9 patients in the small-dose calcium group. Intact PTH decreased by 25% in the large-dose group and increased by 121% in the small-dose group (P = 0.0007 for Delta; P = 0.007 for Delta%). In the 14 patients in whom ionized calcium increased, iPTH decreased. In 10 of 11 patients in whom ionized calcium decreased, iPTH increased. The increase or decrease of ionized calcium was more predictive for changes in iPTH than was the calcium-substitution rate (R-2 = 0.5526 versus 0.3962, respectively). We conclude that the behavior of iPTH can be influenced in a predictive manner by adjusting the calcium-substitution rate during treatment.
引用
收藏
页码:1199 / 1204
页数:6
相关论文
共 24 条
  • [1] Dalteparin-induced alopecia in hemodialysis patients:: reversal by regional citrate anticoagulation
    Apsner, R
    Hörl, WH
    Sunder-Plassmann, G
    [J]. BLOOD, 2001, 97 (09) : 2914 - 2915
  • [2] Simplified citrate anticoagulation for high-flux hemodialysis
    Apsner, R
    Buchmayer, H
    Lang, T
    Unver, B
    Speiser, W
    Sunder-Plassmann, G
    Hörl, WH
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) : 979 - 987
  • [3] Apsner R, 1998, NEW ENGL J MED, V338, P131
  • [4] Bone loss physiology in critically ill patients
    Aris, RM
    Lester, GE
    Ontjes, DA
    [J]. CHEST, 1998, 114 (04) : 954 - 955
  • [6] Carlstedt F, 1998, EUR J CLIN INVEST, V28, P898
  • [7] REDUCING THE HEMORRHAGIC COMPLICATIONS OF HEMODIALYSIS - A CONTROLLED COMPARISON OF LOW-DOSE HEPARIN AND CITRATE ANTICOAGULATION
    FLANIGAN, MJ
    VONBRECHT, J
    FREEMAN, RM
    LIM, VS
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1987, 9 (02) : 147 - 153
  • [8] HOCKEN AG, 1992, CLIN NEPHROL, V37, P36
  • [9] CITRATE ANTICOAGULATION AND DIVALENT-CATIONS IN HEMODIALYSIS
    JANSSEN, MJFM
    HUIJGENS, PC
    BOUMAN, AA
    OE, PL
    VANDERMEULEN, J
    [J]. BLOOD PURIFICATION, 1994, 12 (06) : 308 - 316
  • [10] Regional citrate anticoagulation in continuous venovenous hemodiafiltration
    Kutsogiannis, DJ
    Mayers, I
    Chin, WDN
    Gibney, RTN
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (05) : 802 - 811